BioNTech (NASDAQ:BNTX) Price Target Cut to $125.00 by Analysts at UBS Group

BioNTech (NASDAQ:BNTX) had its target price decreased by analysts at UBS Group from $135.00 to $125.00 in a research report issued on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. UBS Group‘s target price indicates a potential upside of 37.82% from the stock’s previous close.

Several other equities analysts have also weighed in on the stock. Bank of America reiterated a “buy” rating on shares of BioNTech in a report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research note on Friday, October 2nd. BMO Capital Markets cut shares of BioNTech from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $128.00 to $105.00 in a report on Tuesday, September 8th. Morgan Stanley dropped their price objective on shares of BioNTech from $114.00 to $106.00 and set an “overweight” rating on the stock in a research report on Wednesday. Finally, Argus assumed coverage on shares of BioNTech in a report on Thursday, October 8th. They issued a “hold” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $123.60.

BioNTech Trading Up 4.3%

Shares of NASDAQ BNTX traded up $3.78 during trading on Wednesday, hitting $90.70. 1,352,767 shares of the company were exchanged, compared to its average volume of 1,094,356. BioNTech has a 12-month low of $79.52 and a 12-month high of $124.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.80 and a current ratio of 7.85. The company has a fifty day moving average price of $96.14 and a 200-day moving average price of $96.99. The firm has a market capitalization of $22.94 billion, a PE ratio of -11.58 and a beta of 1.28.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The firm had revenue of $122.31 million during the quarter, compared to analysts’ expectations of $180.18 million. During the same period in the prior year, the company posted ($1.60) EPS. The company’s revenue for the quarter was down 59.5% compared to the same quarter last year. As a group, equities research analysts expect that BioNTech will post -6.62 EPS for the current year.

Insider Activity at BioNTech

In other news, CEO Ugur Sahin sold 36,209 shares of the company’s stock in a transaction that occurred on Friday, October 9th. The stock was sold at an average price of $95.37, for a total transaction of $3,453,252.33. Following the completion of the sale, the chief executive officer owned 36,209 shares in the company, valued at $3,453,252.33. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 807,209 shares of company stock worth $79,246,837 in the last three months. 19.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On BioNTech

A number of hedge funds have recently added to or reduced their stakes in the company. Flossbach Von Storch SE acquired a new stake in shares of BioNTech in the 2nd quarter valued at approximately $207,142,000. Bank of America Corp DE lifted its holdings in BioNTech by 22.6% in the first quarter. Bank of America Corp DE now owns 903,029 shares of the company’s stock valued at $80,261,000 after acquiring an additional 166,432 shares during the period. Assenagon Asset Management S.A. boosted its position in shares of BioNTech by 79.7% during the 3rd quarter. Assenagon Asset Management S.A. now owns 760,675 shares of the company’s stock worth $74,774,000 after purchasing an additional 337,412 shares in the last quarter. First Trust Advisors LP boosted its position in shares of BioNTech by 116.0% during the 1st quarter. First Trust Advisors LP now owns 839,991 shares of the company’s stock worth $74,658,000 after purchasing an additional 451,124 shares in the last quarter. Finally, Candriam S.C.A. boosted its position in shares of BioNTech by 4.7% during the 3rd quarter. Candriam S.C.A. now owns 520,972 shares of the company’s stock worth $51,399,000 after purchasing an additional 23,442 shares in the last quarter. Institutional investors and hedge funds own 15.52% of the company’s stock.

Key BioNTech News

Here are the key news stories impacting BioNTech this week:

• Positive Sentiment: BioNTech reported Q3 EPS of $1.99 versus analysts’ $0.76 estimate and revenue of $1.49 billion versus $1.17 billion expected. It raised its 2026 revenue guidance to €1.7–€1.9 billion and reported €16.2 billion in cash, cash equivalents and investments. BioNTech beats third-quarter forecasts and raises revenue guidance despite pipeline setbacks
• Positive Sentiment: Clinical updates offered potential support for BioNTech’s oncology strategy: the company reported promising survival data for gotistobart in previously treated squamous non-small cell lung cancer and advanced a Phase 3 trial of pumitamig in triple-negative breast cancer. It also launched its updated COVID-19 vaccine in multiple regions. BioNTech third-quarter results and corporate update
• Neutral Sentiment: Morgan Stanley lowered its price target from $114 to $106, and Wells Fargo cut its target from $140 to $125. Both firms maintained Overweight ratings, indicating continued optimism despite reduced targets. Morgan Stanley recommendations Wells Fargo recommendations
• Negative Sentiment: A Seeking Alpha analysis downgraded the stock to Hold, citing ongoing cash burn, a narrowing pipeline and reliance on pumitamig and gotistobart. It argued that declining liquid assets and concentrated development bets remain risks despite reported quarterly profit. BioNTech Q3: Bristol Myers Revenue Masks A Narrowing Oncology Bet

About BioNTech

BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing medicines and vaccines based on messenger RNA and other immunotherapy technologies. The company’s research programs address cancer, infectious diseases, and other serious medical conditions.

BioNTech’s oncology portfolio includes individualized and off-the-shelf cancer immunotherapies, including mRNA-based treatments, cell therapies, antibody-based therapies, and immune-modulating approaches. Its infectious-disease activities include vaccine programs developed through proprietary platforms and collaborations.

In collaboration with Pfizer, BioNTech developed Comirnaty, an mRNA-based COVID-19 vaccine.